Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major…
<!-- Name:DistributionId Value:8782715 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Small Pharma Inc.
Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive…
LONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration…
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New…
Last patient last visit complete in SPL026 Phase IIa clinical trial with topline results expected early in Q1 European patent granted for synthetic manufacturing process of key…
Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting…
Small Pharma to Participate in November Investor and Healthcare Conferences
LONDON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting…
Small Pharma Enters Into Automatic Share Purchase Plan
LONDON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting…
Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug…
LONDON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting…
Small Pharma to Participate in the 34th Annual Roth Conference
LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuroscience company focused on psychedelic-assisted therapies…
World’s First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder…
In the Phase I clinical trial, participants were administered SPL026 and underwent a 20-minute psychedelic experience Phase I full dataset demonstrates consistent dose related effects…
Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director
LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted…